Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Notes Payables (2022 - 2025)

Bioregenx has reported Notes Payables over the past 4 years, most recently at $1.0 million for Q4 2025.

  • For Q4 2025, Notes Payables rose 13.58% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, up 13.58%, while the annual FY2025 figure was $1.0 million, 13.58% up from the prior year.
  • Notes Payables for Q4 2025 was $1.0 million at Bioregenx, down from $1.0 million in the prior quarter.
  • Over five years, Notes Payables peaked at $1.0 million in Q3 2025 and troughed at $12590.0 in Q1 2023.
  • A 4-year average of $601093.6 and a median of $850813.0 in 2024 define the central range for Notes Payables.
  • Biggest five-year swings in Notes Payables: soared 6657.85% in 2024 and later increased 3.69% in 2025.
  • Year by year, Notes Payables stood at $40970.0 in 2022, then soared by 816.97% to $375681.0 in 2023, then surged by 135.11% to $883271.0 in 2024, then rose by 13.58% to $1.0 million in 2025.
  • Business Quant data shows Notes Payables for BRGX at $1.0 million in Q4 2025, $1.0 million in Q3 2025, and $970117.0 in Q2 2025.